Influence of MAO-inhibitors, neuroleptics, morphine, mescaline, divascan, aconitine, and pyrogenes on prostaglandin-biosynthesis.
D000157:Aconitine / Q000494:pharmacology*; D031841:Aconitum / Q000031:analogs & derivatives*; D000323:Adrenochrome / Q000031:analogs & derivatives* / Q000494:pharmacology; D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology*; D001241:Aspirin / Q000494:pharmacology; D002746:Chlorpromazine / Q000494:pharmacology; D003078:Colchicine / Q000494:pharmacology; D004837:Epinephrine / Q000494:pharmacology; D005260:Female; D006220:Haloperidol / Q000031:analogs & derivatives / Q000494:pharmacology; D006246:Harmaline / Q000494:pharmacology; D066298:In Vitro Techniques; D045563:Indolequinones; D007213:Indomethacin / Q000494:pharmacology; D007679:Kidney Medulla / Q000187:drug effects / Q000378:metabolism; D008297:Male; D008635:Mescaline / Q000494:pharmacology*; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology*; D009020:Morphine / Q000494:pharmacology*; D010624:Phenelzine / Q000494:pharmacology; D010659:Phenylhydrazines / Q000494:pharmacology; D011453:Prostaglandins / Q000096:biosynthesis*; D011749:Pyrogens / Q000494:pharmacology*; D011817:Rabbits; D012110:Reserpine / Q000494:pharmacology; D012664:Semicarbazones / Q000494:pharmacology
D014150:Antipsychotic Agents; D045563:Indolequinones; D008996:Monoamine Oxidase Inhibitors; D010659:Phenylhydrazines; D011453:Prostaglandins; D011749:Pyrogens; D012664:Semicarbazones; D000323:Adrenochrome; D009020:Morphine; D012110:Reserpine; C009742:iprazochrome; D006246:Harmaline; D006220:Haloperidol; D010624:Phenelzine; D001241:Aspirin; D008635:Mescaline; D003078:Colchicine; D002746:Chlorpromazine; D000157:Aconitine; D007213:Indomethacin; D004837:Epinephrine